| Literature DB >> 30742488 |
Stanislaw J Gabryszewski1, Tania Wong Fok Lung1, Medini K Annavajhala2,3, Kira L Tomlinson1, Sebastian A Riquelme1, Ibrahim N Khan1, Loreani P Noguera1, Matthew Wickersham1, Alison Zhao1, Arielle M Mulenos4, David Peaper5, Jonathan L Koff4, Anne-Catrin Uhlemann2,3, Alice Prince1.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a versatile human pathogen that is associated with diverse types of infections ranging from benign colonization to sepsis. We postulated that MRSA must undergo specific genotypic and phenotypic changes to cause chronic pulmonary disease. We investigated how MRSA adapts to the human airway to establish chronic infection, as occurs during cystic fibrosis (CF). MRSA isolates from patients with CF that were collected over a 4-year period were analyzed by whole-genome sequencing, transcriptional analysis, and metabolic studies. Persistent MRSA infection was associated with staphylococcal metabolic adaptation, but not changes in immunogenicity. Adaptation was characterized by selective use of the tricarboxylic acid cycle cycle and generation of biofilm, a means of limiting oxidant stress. Increased transcription of specific metabolic genes was conserved in all host-adapted strains, most notably a 10,000-fold increase in fumC, which catalyzes the interconversion of fumarate and malate. Elevated fumarate levels promoted in vitro biofilm production in clinical isolates. Host-adapted strains preferred to assimilate glucose polymers and pyruvate, which can be metabolized to generate N-acetylglucosamine polymers that comprise biofilm. MRSA undergoes substantial metabolic adaptation to the human airway to cause chronic pulmonary infection, and selected metabolites may be useful therapeutically to inhibit infection.Entities:
Keywords: bacterial metabolic adaptation; chronic pulmonary infection; cystic fibrosis
Mesh:
Substances:
Year: 2019 PMID: 30742488 PMCID: PMC6670030 DOI: 10.1165/rcmb.2018-0389OC
Source DB: PubMed Journal: Am J Respir Cell Mol Biol ISSN: 1044-1549 Impact factor: 6.914
List of Primers Used in this Study
| Primers Used for qRT-PCR | |||
|---|---|---|---|
| Target Gene | Gene | Forward Primer Sequence | Reverse Primer Sequence |
| Citrate synthase | 5′-gatctagctgaaaacgcgca-3′ | 5′-ctgtcattggatgcacgtga-3′ | |
| Aconitase | 5′-gcaaacatggcaccagagta-3′ | 5′-tttggtcctgaaagcgatgc-3′ | |
| Isocitrate dehydrogenase | 5′-ccagctgagcatgatgttgt-3′ | 5′-ggagctgtaccatgtgttgc-3′ | |
| 2-oxoglutarate dehydrogenase | 5′-gccgtgttacatgatgagca-3′ | 5′-caccatattgcgcttcccaa-3′ | |
| 2-oxoglutarate dehydrogenase | 5′-tgctatcatcggcgaaggta-3′ | 5′-tgacaccattttcacgagca-3′ | |
| Succinyl coA synthetase | 5′-tagaggtaaagcaggcggag-3′ | 5′-cccttcttcagacgccatca-3′ | |
| Succinyl coA synthetase | 5′-caccatttgctgcagactca-3′ | 5′-atcacacctggacagttcgg-3′ | |
| Succinate dehydrogenase | 5′-tgtatggtggcgacttcctt-3′ | 5′-ttgttgtccagttgttgccc-3′ | |
| Succinate dehydrogenase | 5′-ggaccacgtatgccagagaa-3′ | 5′-ctgtaagccaccagtaccca-3′ | |
| Fumarase | 5′-atgcttgaccgttgcgaaat-3′ | 5′-agcgccttcaatgttccatg-3′ | |
| Malate:quinone oxidoreductase | 5′-atgctatcgtgatgaattcaaagg-3′ | 5′-ttatttaacttgtaaatacttagttac-3′ | |
| Glucose-6-phosphate 1-dehydrogenase | 5′-caaacacatcccatgtttaatcaca-3′ | 5′-tggaatattgatggaaacaacttacg-3′ | |
| Glyceraldehyde 3-phosphate dehydrogenase | 5′-attgaagcaggcgctaaaaa-3′ | 5′-ctgtgaggtgcgtcttgtgt-3′ | |
| Glycolytic operon regulator | 5′-ttgcaagcacagcaaaagc-3′ | 5′-ccatatgttcgcttaaacttcg-3′ | |
| c-di-AMP synthase | 5′-tgcggttggtatttcagaag-3′ | 5′-tttcttttgaaagcgtgtgc-3′ | |
| c-di-AMP phosphodiesterase | 5′-ttagtcgatgggcaactgag-3′ | 5′-ttaattgggcacgataacca-3′ | |
| Intercellular adhesion A | 5′-acacttgctggcgcagtcaa-3′ | 5′-tctggaaccaacatccaaca-3′ | |
| Intercellular adhesion B | 5′-tccttatggcttgatgaatgacg-3′ | 5′-ctaatctttttcatggaatccgtcc-3′ | |
| Intercellular adhesion C | 5′-atgggttataactacgaacgtg-3′ | 5′-cgtgcaaatacccaagataac-3′ | |
| Intercellular adhesion D | 5′-atggtcaagcccagacagag-3′ | 5′-agtattttcaatgtttaaagcaa-3′ | |
| Lipoteichoic acid synthase | 5′-attctcatttaattacattgactaacc-3′ | 5′-ccatcaactgttgcatcacct-3′ | |
Figure 1.Characterization of cystic fibrosis (CF) host-adapted methicillin-resistant Staphylococcus aureus (MRSA) strains. (A) Timeline and sequence type (ST) of MRSA isolation from patients A, B, and C. All samples were harvested from sputum, with the exception of A6 (*, blood) and B3 (**, pleural fluid). A2–A6 were one-SNP variants of ST105 (***). (B) Phylogenetic tree of MRSA isolates from the A series, with an ST-matched non-CF isolate (CP011147) serving as a reference. Branch lengths represent the number of nucleotide substitutions per site. (C) Schematic diagram showing the number of nonsynonymous mutations (NSMs) observed among A-series MRSA isolates as compared with a non-CF reference strain, and their associated pathway. (D) Growth curves of the laboratory strain of MRSA USA300 and the isolates from the A, B, and C series in Luria-Bertani broth. Data shown are from four biological replicates in triplicate. (E) Intracellular bacterial persistence of the MRSA isolates from patients A, B, and C in THP-1 cells. Data shown are from two independent experiments with each sample in triplicate. (F) Cytokines from 16HBE cells infected with MRSA isolates. (G) Cytokines from THP-1 cells infected with MRSA isolates. (H) IFN-β production by 16HBE cells 24 hours after S. aureus infection. Data are shown for three independent experiments in triplicate. (I) Impact of the superoxide generator paraquat on growth of the MRSA isolates. Data shown are from two independent experiments in triplicate. Statistical significance was determined by one-way ANOVA, ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. OD = optical density; Ref = reference non-CF isolate CP011147 strain.
Clinical Characteristics of the Patients from Whom MRSA Isolates were Collected
| Patients’ Clinical Characteristics | |||
|---|---|---|---|
| Patient A | Patient B | Patient C | |
| Age | 45 | 27 | 41 |
| Sex | Female | Male | Male |
| Sweat chloride values, mmol/L | 97 | 87 | 34/36 |
| CFTR genotype | ∆F508/∆F508 | R1162X/R347P | c.273+1G>A and c.3718-2477C>T with 7T/7T poly-T variants |
| FEV1 | |||
| Most recent, L, % predicted | 1.88 L (69%) | 3.24 L (76%) | 0.99 L (23%) |
| At admission, L, % predicted | 1.37 L (51%) | 2.93 L (70%) | 0.87 L (20%) |
| CF-related complications | CF-related diabetes, pancreatic insufficiency | Pancreatic insufficiency | Pancreatic insufficiency |
| Acute presentation, 02/2017 | Pneumonia with bacteremia | Pneumonia with right pleural effusion | Lobar pneumonia |
| Site of specimen collection | Sputum (A1–A5), blood (A6) | Sputum (B1–B2), BAL fluid (B3) | Sputum (C1–C3) |
| Period of MRSA collection | 2013–2017 | 2013–2017 | 2015–2017 |
| 2013 (A1) | 2013 (B1) | 2015 (C1) | |
| 2014 (A2) | 2016 (B2) | 2016 (C2) | |
| 2015 (A3) | 2017 (B3) | 2017 (C3) | |
| 2016 (A4) | |||
| 2017 (A5–A6) | |||
| Bacteriology, others (2017) | MSSA, | MSSA, | |
Definition of abbreviations: CF = cystic fibrosis; FEV1 = forced expiratory volume in 1 second; MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-sensitive S. aureus;
List of Nonsynonymous Mutations that Differed between at Least One of the A-Series Strains and a Sequence Type–matched, Non–Cystic Fibrosis Strain, or among Strains Harvested from a Single Patient
| Isolate | Number of NSMs | Implicated Genes and Pathways |
|---|---|---|
| A vs. reference | 80 | Adhesion ( |
| DNA replication and repair ( | ||
| Metabolism ( | ||
| Post-translational processing and proteolysis ( | ||
| Redox homeostasis ( | ||
| Structural homeostasis ( | ||
| Transcriptional regulation ( | ||
| Translation ( | ||
| Transport ( | ||
| Other ( | ||
| Unknown | ||
| A | 27 | Adhesion ( |
| Metabolism ( | ||
| Post-translational processing ( | ||
| Transcriptional regulation ( | ||
| Translation ( | ||
| Transport ( | ||
| B | 17 | |
| C | 27 |
Definition of abbreviation: NSMs = nonsynonymous mutations.
Figure 2.Biofilm-forming ability of the MRSA isolates. (A) Summary of NSMs observed in gdpP and dacA in MRSA isolates and schematic of the role of these genes in c-di-AMP metabolism. (B) Biofilm formation of the MRSA clinical isolates, MRSA strain USA300, and Pseudomonas aeruginosa PAO1. Data shown are from at least three independent experiments in triplicate. Statistical significance was determined by one-way ANOVA, ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. (C) Transcription of dacA and gdpP from MRSA isolates grown in biofilm-inducing conditions. Data are shown for four biological replicates. Statistical significance was determined by Mann-Whitney t test, *P < 0.05. (D) Effect of Congo Red (CR) on the growth of the MRSA isolates. The transcription of ltaS, which controls the synthesis of the cell wall component leipoteichoic acid, is also shown. (E) Quantification of extracellular DNA from the MRSA isolates. Data represent two independent experiments performed in triplicate. Statistical significance was determined by one-way ANOVA, ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. (F) Transcription of the intercellular adhesion locus (icaA/B/C/D) from the clinical MRSA strains. For C, D, and F, RQ = relative quantification to wild-type (WT) LAC; TS = tryptic soy.
Figure 3.Metabolic adaptation of the host-adapted MRSA isolates. (A and B) Carbon source assimilation of the clinical strains relative to USA300 (A) and USA300 alone (B). The heatmap color intensity corresponds to the absorbance (OD590) of the indicated strain in the presence of the indicated carbon source, normalized to the absorbance (OD590) of USA300 in the same carbon source. Data represent three independent experiments. (C) Schematic diagram showing the major metabolic pathways in S. aureus and the production of polysaccharide intercellular adhesin (PIA). (D) Transcription of bacterial genes involved in glycolysis, the pentose phosphate pathway, and the tricarboxylic acid (TCA) cycle. Data shown are from four biological replicates. Statistical significance was determined by Mann-Whitney t test, *P < 0.05 and **P < 0.01.
Figure 4.Role of fumC in S. aureus pathogenesis in vivo. (A) Bacterial enumeration from the BAL fluid (BALF) and lungs of mice infected with WT USA300 or the MRSA isolates A1, A5, and A6. Data are from three independent experiments done at least in triplicate. (B) Immune cell recruitment in the lungs of infected mice. Data shown are from at least two independent experiments. (C) Cytokine analysis of the BALF from infected mice. (D) Bacterial enumeration in the BALF and lungs of mice infected with WT JE2 or the fumC mutant. (E) Growth of WT and the fumC mutant in Luria-Bertani medium. Data from three independent experiments done in triplicate. (F) Cytokine analysis from the BALF of infected mice, n ≥ 4 for each infected group. Statistical significance was determined by one-way ANOVA; ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05.
Figure 5.Fumarate enhances biofilm formation. (A and B) Bacterial growth and biofilm formation of CF host-adapted strains (WT USA300, WT JE2, and fumC mutant) in the presence of increasing concentrations of (A) fumarate and (B) malate. Data represent at least three independent experiments done in triplicate. Purple asterisks denote statistical difference respective to WT USA300 at the given concentration of fumarate or malate. Colored asterisks show statistical difference within the given strain across different concentrations of fumarate or malate respective to the untreated condition. Statistical significance was determined by one-way ANOVA; ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. (C) Growth and (D) biofilm-forming ability as determined by crystal violet staining of MRSA strains in the presence of various concentrations of the TCA intermediates citrate, acetate, and succinate, as assessed in three independent experiments.